Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02230384Phase 2Completed

Novel Smoking Cessation Drug for Schizophrenia

Role: lead

NCT01793935Not ApplicableCompleted

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

Role: lead

NCT01010204Phase 4Completed

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

Role: lead

All 3 trials loaded